Cannabidiol as potential treatment in refractory pediatric epilepsy

Maria Chiara Paolino, Alessandro Ferretti, Laura Papetti, Maria Pia Villa, Pasquale Parisi

Research output: Contribution to journalArticlepeer-review


In recent years there has been great scientific and public interest focused on the therapeutic potential of compounds derived from cannabis for the treatment of refractory epilepsy in children. From in vitro and in vivo studies on animal models, cannabidiol (CBD) appears to be a promising anticonvulsant drug with a favorable side-effect profile. In humans, CBD efficacy and safety is not supported by well-designed trials and its use has been described by anecdotal reports. It will be necessary to investigate CBD safety, pharmacokinetics and interaction with other anti-epileptic drugs (AEDs) alongside performing double-blinded placebo-controlled trials in order to obtain conclusive data on its efficacy and safety in children.

Original languageEnglish
Pages (from-to)17-21
Number of pages5
JournalExpert Review of Neurotherapeutics
Issue number1
Publication statusPublished - Jan 2 2016


  • cannabidiol
  • Cannabis
  • CBD
  • epilepsy
  • refractory epilepsy in children

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)
  • Pharmacology (medical)


Dive into the research topics of 'Cannabidiol as potential treatment in refractory pediatric epilepsy'. Together they form a unique fingerprint.

Cite this